SCHEMBL21873587

SCHEMBL21873587

CC(C)(C)[Si](OCC(CO)OCCn1cnc2c(NC(=O)c3ccccc3)ncnc21)(c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
ABL1 P00519 1/20 0.37
P2RY1 P47900 2/20 0.37
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
ADORA2A P29274 4/20 0.36
ADORA1 P30542 4/20 0.36
TMIGD3 P0DMS9 3/20 0.36
EGFR P00533 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
FGFR1 P11362 1/20 0.34
HTT P42858 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30688740 1.00 FLT4 (0.37) FLT4KDRABL1P2RY1RAB9A
SCHEMBL21873584 1.00 FLT4 (0.37) FLT4KDRABL1P2RY1RAB9A
SCHEMBL21873563 0.87 HDAC1 (0.39) FLT4KDRABL1ADORA1TMIGD3
SCHEMBL21873560 0.87 HDAC1 (0.39) FLT4KDRABL1ADORA1TMIGD3
SCHEMBL21873624 0.83 LMNA (0.48) ADORA2AADORA1EGFRFGFR1
SCHEMBL21873622 0.83 LMNA (0.48) ADORA2AADORA1EGFRFGFR1
SCHEMBL30688739 0.83 LMNA (0.48) ADORA2AADORA1EGFRFGFR1
SCHEMBL21873561 0.81 HDAC1 (0.42) FLT4KDRABL1P2RY1ADORA1
SCHEMBL21873559 0.81 HDAC1 (0.42) FLT4KDRABL1P2RY1ADORA1
SCHEMBL20833463 0.78 RAB9A (0.48) FLT4KDRABL1P2RY1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110678447-B Modified nucleic acid monomer compounds and oligonucleotide analogues 卫材R&D管理有限公司 2023-12-12 CN disclosed
EP-3643706-B1 MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES EISAI R&D MAN CO LTD (JP) 2023-11-15 EP disclosed
US-11208429-B2 Modified nucleic acid monomer compound and oligonucleic acid analog EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-12-28 US disclosed
EP-3643706-A9 MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG Eisai R&D Management Co., Ltd. (JP) 2020-09-23 EP disclosed
US-20200216488-A1 MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-07-09 US disclosed
EP-3643706-A1 MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG Eisai R&D Management Co., Ltd. (JP) 2020-04-29 EP disclosed
CN-110678447-A Modified nucleic acid monomer compounds and oligonucleotide analogs 卫材R&D管理有限公司 2020-01-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216488-A1 MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG POLRMT, DERA, PCNA FLT4 3692/4885KDR 2475/4885ABL1 4291/4885
US-11208429-B2 Modified nucleic acid monomer compound and oligonucleic acid analog POLRMT, DERA, PCNA FLT4 3692/4885KDR 2475/4885ABL1 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.